ProteoNic 2G UNic technology licensed by Ginkgo Bioworks

Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been licensed by Ginkgo Bioworks (NYSE: DNA) for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA).

The project, funded through BARDA’s Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), aims to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (MAbs) to treat infection by filoviruses, such as Ebola (EBOV) and Sudan Virus (SUDV)

The project, with a total value of up to $22.2 million, brings together a team led by Ginkgo Bioworks that includes Advanced BioScience Laboratories (ABL), Isolere Bio by Donaldson, NeuImmune, and ProteoNic. Collectively, the project team will develop and integrate innovative technologies spanning the full MAb production process, from cell line development through purification, to create a more rapid, scalable, and cost-effective biomanufacturing solution for critical medical countermeasures. The companies first teamed up in March 2024.